Catalyst Trusteeship Limited, acting as Debenture Trustee, has officially announced the release of a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Ltd. This action, dated August 11, 2026, pertains to securing obligations of API Holdings Limited concerning non-convertible debentures. The release impacts the shareholding structure and is a standard disclosure under SEBI regulations.
Share Pledge Released
Catalyst Trusteeship Limited has completed the release of a pledge on a substantial quantity of equity shares in Thyrocare Technologies Ltd. The disclosure, made on August 13, 2026, confirms the release of 1,75,00,000 equity shares. These shares were held under encumbrance to secure the obligations of API Holdings Limited, specifically related to issued, unlisted, redeemable, non-convertible debentures.
Transaction Details
The release of pledge was executed on August 11, 2026. Prior to this release, Catalyst Trusteeship Limited, in its capacity as Debenture Trustee, held approximately 60.92% of the total share capital of Thyrocare Technologies Ltd. After the release, the holding has reduced to 49.93% of the equity shares. This transaction signifies a change in the pledged share volume and affects the overall control and free float of Thyrocare Technologies Ltd.
Company Shareholding Structure
Before the release of pledge, Thyrocare Technologies Ltd’s equity share capital was 15,91,65,315 shares with a face value of ₹10 each. Post-release, the total equity share capital remains the same, but the number of shares carrying voting rights held by Catalyst Trusteeship Limited has reduced. The diluted share capital after the transaction stands at 15,96,30,252 equity shares.
Source: BSE
